Welzel, Tania Mara <br/><br/>
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.  [electronic resource] 

 -  Hepatology (Baltimore, Md.)  Jun 2009 
 - 1847-58 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural 
<br/><br/><label>ISSN: </label>1527-3350 
<br/><br/><label>Standard No.: </label>10.1002/hep.22877  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antiviral Agents--administration & dosage<br/>Drug Therapy, Combination<br/>Female<br/>Hepatitis C, Chronic--complications<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Liver Cirrhosis--etiology<br/>Male<br/>Middle Aged<br/>Polyethylene Glycols--administration & dosage<br/>Polymorphism, Genetic<br/>Recombinant Proteins<br/>Ribavirin--administration & dosage<br/>Time Factors